Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Evercore ISI Downgrades Amylyx Pharmaceuticals inc. (AMLX) to In Line
March 8, 2024 9:27 AM ESTEvercore ISI analyst Umer Raffat downgraded Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) from Outperform to In Line.
The analyst comments "Amylyx failed in their Ph 3 ALS trial today. We thought they had a real shot heading into this study ... not just based on prior... More
Amylyx (AMLX) Falls 70% After Phase 3 PHOENIX Trial of AMX0035 in ALS Did Not Meet Prespecified Primary or Secondary Endpoints
March 8, 2024 7:13 AM ESTAmylyx (NASDAQ: AMLX) Falls 70% After Phase 3 PHOENIX Trial of AMX0035 in ALS Did Not Meet Prespecified Primary or Secondary Endpoints
HOENIX Study Did Not Meet Prespecified Primary or Secondary EndpointsData From 664-Participant Study Reinforce That AMX0035 is Generally Safe and... MoreAmylyx Pharmaceuticals (AMLX) Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
March 8, 2024 7:00 AM ESTAmylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA in Canada) in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its... More
Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $32 at Mizuho
March 8, 2024 6:34 AM ESTMizuho analyst Graig Suvannavejh raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $32.00 (from $27.00) while maintaining a Buy rating.... More
